Optical coherence tomography findings after chronic total occlusion interventions: Insights from the "AngiographiC evaluation of the everolimus-eluting stent in chronic Total occlusions" (ACE-CTO) study (NCT01012869)
Creators
- Sherbet, Daniel P.1
- Christopoulos, Georgios1
- Karatasakis, Aris1
- Danek, Barbara Anna1
- Kotsia, Anna1
- Navara, Rachita1
- Michael, Tesfaldet T.1
- Roesle, Michele1
- Rangan, Bavana V.1
- Haagen, Donald1
- Garcia, Santiago2
- Maniu, Calin3
- Pershad, Ashish4
- Abdullah, Shuaib M.1
- Hastings, Jeffrey L.1
- Kumbhani, Dharam J.1
- Luna, Michael1
- Addo, Tayo1
- Banerjee, Subhash1
- Brilakis, Emmanouil S.1
- 1. VA North Texas Healthcare System and University of Texas Southwestern Medical Center, Dallas, TX (United States)
- 2. Minneapolis VA Healthcare System and University of Minnesota, Minneapolis, MN (United States)
- 3. Bon Secours Health System, Suffolk, VA (United States)
- 4. Banner Good Samaritan Medical Center, Phoenix, AZ (United States)
Description
Background: There is limited information on optical coherence tomography (OCT) findings after percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs). OCT allows high resolution imaging that can enhance understanding of the vascular response after stenting of chronically occluded vessels. Methods: The Angiographic Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions (ACE-CTO) study collected angiographic and clinical outcomes from 100 patients undergoing CTO PCI with the everolimus-eluting stent (EES). OCT was performed 8-months post stenting in 62 patients. Every third frame was analyzed throughout the course of the stented arterial segment. Lumen contours were semi-automatically traced and stent struts were manually delineated, with automatic measurement of the strut to lumen distance. Struts on the luminal side of the lumen contour were classified as malapposed if the distance to the lumen contour exceeded 0.108 mm. Results: A total of 44,450 struts in 6047 frames were analyzed, of which 4113 9.3%, 95% confidence intervals [CI] 9.0% to 9.5%) were malapposed and 1230 (2.8%, 95% CI 2.6% to 2.9%) were uncovered. Fifty-five of 62 patients (88.7%, 95% CI 78.5% to 98.4%) had at least one malapposed stent strut and 50 patients (80.7%, 95% CI 69.2% to 88.6%) had at least one uncovered stent strut. Mean strut-intimal thickness of the apposed and malapposed struts was 0.126 ± 0.140 mm and − 0.491 ± 0.440 mm, respectively. Conclusion: High rates of stent strut malapposition and incomplete stent strut coverage were observed after CTO PCI using EES, highlighting unique challenges associated with stent implantation in CTOs. - Highlights: • Percutaneous coronary intervention with drug-eluting stents for chronic total occlusion is associated with a 40% rate of binary in-stent restenosis at 8 months • Of patients who receive a drug eluting stent for a chronic total occlusion 88.7% will have stent strut malapposition and 80.7% will have incomplete strut coverage on follow-up • Target lesion revascularization occurred in 39% of patients who underwent revascularization for a chronic total occlusion at 8 months
Availability note (English)
Available from http://dx.doi.org/10.1016/j.carrev.2016.04.002Additional details
Identifiers
- DOI
- 10.1016/j.carrev.2016.04.002;
- PII
- S1553-8389(16)30106-3;
Publishing Information
- Journal Title
- Cardiovascular Revascularization Medicine (Print)
- Journal Volume
- 17
- Journal Issue
- 7
- Journal Page Range
- p. 444-449
- ISSN
- 1553-8389
INIS
- Country of Publication
- Netherlands
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 48093379
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- BIOMEDICAL RADIOGRAPHY; CORONARIES; EVALUATION; PATIENTS; PHENOBARBITAL; RESOLUTION; THICKNESS; TOMOGRAPHY; WHO
- Descriptors DEC
- ANESTHETICS; ANTICONVULSANTS; ARTERIES; AZINES; BARBITURATES; BLOOD VESSELS; BODY; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DIAGNOSTIC TECHNIQUES; DIMENSIONS; DRUGS; HETEROCYCLIC COMPOUNDS; HYPNOTICS AND SEDATIVES; INTERNATIONAL ORGANIZATIONS; MEDICINE; NUCLEAR MEDICINE; ORGANIC COMPOUNDS; ORGANIC NITROGEN COMPOUNDS; ORGANIC OXYGEN COMPOUNDS; ORGANS; PYRIMIDINES; RADIOLOGY
Optional Information
- Copyright
- Copyright (c) 2016 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.